<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Catalyst Pharmaceuticals, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Catalyst Pharmaceuticals, Inc.

    Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Patrick J. McEnany
    • FOUNDED
      2002
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Elevate Nutrition Inc.

    Elevate Nutrition Inc.

    Elevate is the first of its kind, a line of high-performance nutritional supplemen...

    Elevate is the first of its kind, a line of hig...

    Amount Raised:    $156,102.00
    Fundraising Status:    EC
    Filing Type:    CF
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Royal Philips NV

    Royal Philips NV

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...

    Filing Type:    PU
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    Rexahn Pharmaceuticals, Inc.

    Rexahn Pharmaceuticals, Inc.

    Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...

    Rexahn Pharmaceuticals is a clinical stage biop...

    Filing Type:    PU
    Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc.

    Since Aclaris was founded in 2012, our focus has been innovation to help people wi...

    Since Aclaris was founded in 2012, our focus ha...

    Filing Type:    PU
    Helius Medical Technologies, Inc.

    Helius Medical Technologies, Inc.

    Helius Medical Technologies, Inc. (Helius) is a neurotech company in the medical d...

    Helius Medical Technologies, Inc. (Helius) is a...

    Filing Type:    PU
    Neurotez Inc.

    Neurotez Inc.

    We have used biochemical, molecular & cell biology and in vivo models to screen, i...

    We have used biochemical, molecular & cell biol...

    Amount Raised:    $7,656.00
    Fundraising Status:    EC
    Filing Type:    CF
    Athersys, Inc.

    Athersys, Inc.

    We are an international biotechnology company that is focused in the field of rege...

    We are an international biotechnology company t...

    Filing Type:    PU
    Audentes Therapeutics, Inc.

    Audentes Therapeutics, Inc.

    Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...

    Audentes Therapeutics is a leading AAV-based ge...

    Filing Type:    PU
    Sarepta Therapeutics, Inc.

    Sarepta Therapeutics, Inc.

    Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...

    Sarepta Therapeutics is a U.S. commercial-stage...

    Filing Type:    PU
    Scholar Rock Holding Corporation

    Scholar Rock Holding Corporation

    Scholar Rock is a biopharmaceutical company focused on the discovery and developme...

    Scholar Rock is a biopharmaceutical company foc...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.